Psoriasis
Conditions
Keywords
Moderate to severe plaque psoriasis, PASI, secukinumab, monoclonal antibody, Turkish population
Brief summary
Secukinumab targets a different interleukin and has potential to be used as alternative to existing treatments. This study will provide clinical data with respect to efficacy through Psoriasis Area and Severity Index (PASI) at 16 weeks, safety/tolerability of secukinumab and evaluate the impact of the treatment on quality of life and work productivity in subjects with moderate to severe plaque psoriasis in the Turkish population.
Detailed description
To demonstrate the efficacy of secukinumab in subjects with moderate to severe plaque psoriasis based on the percentage of PASI 90 responder patients at Week 16 as compared to baseline Evaluation of onset of efficacy measured by the percentage of patient achieving PASI 75 and PASI 90 at week 4 The efficacy of treatment using Investigator's Global Assessment modified 2011 (IGA mod 2011) at week 4 and week 16 Work productivity (measured with WPAI-PSO) at Week 16 Changes in quality of life measured with the Dermatology Life Quality Index (DLQI) at Week 16 Health assessment questionnaire -Disability index (HAQ-DI) in patients with psoriatic arthritis (PsA)
Interventions
DRUGSecukinumab Cosentyx TM
Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit. First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator * Diagnosis of chronic plaque psoriasis for at least 6 months before enrollment * Patients who were evaluated as candidates for systemic therapy, defined as having psoriasis intolerant or /and inadequately controlled by: topical treatment (including topical corticosteroid) and/or phototherapy and/or any previous systemic treatment for psoriasis or any previous treatment with biologic agents
Exclusion criteria
* Forms of psoriasis other than plaque psoriasis * Drug-induced psoriasis * Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA * Pregnant or nursing (lactating) women * Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound the evaluation of the benefit of secukinumab * Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions) * Pre-existing or recent-onset central or peripheral nervous system demyelinating disorders * Significant medical problems, including but not limited to the following: uncontrolled hypertension, congestive heart failure * Active systemic infections during the 2 weeks prior to enrollment * History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection * Past medical history record of, or current infection with, human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to enrollment * History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years * History or evidence of ongoing alcohol or drug abuse, within the last 6 months prior to enrollment * Plans for administration of live vaccines during the study period or in the 6 weeks prior to enrollment * Not willing to limit UV light exposure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of PASI 90 responder patients at Week 16 as compared to baseline | 16 week | The primary endpoint has been chosen as percentage of PASI 90 responder patients. PASI 90 is accepted as clear or almost clear of psoriatic lesions which are the ultimate goal of treatment in plaque psoriasis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of onset of efficacy measured by the percentage of patient achieving PASI 75 and PASI 90 at week 4 | 4 week | Patients, who achieved PASI 75 and PASI 90 response at week 4 will be counted by using frequencies and percentages (a subject is defined as a PASI 90 responder if the PASI score is reduced by 90% or more compared to baseline visit) |
| The efficacy of treatment using Investigator's Global Assessment modified 2011 (IGA mod 2011) at week 4 and week 16 | 4 and 16 week | Investigator's Global Assessment (IGA mod 2011) score will be explained by using descriptive statistics at week 4 and week 16. Change between week 4 and week 16 comparing to baseline |
| Changes in quality of life measured with the Dermatology Life Quality Index (DLQI) at Week 16 | 16 week | Changes in quality of life measured with Dermatology Life Quality Index (DLQI) through visits will be evaluated by using Repeated Measures ANOVA test. |
| Health assessment questionnaire -Disability index (HAQ-DI) in patients with psoriatic arthritis (PsA) | 16 week | Health Assessment Questionnaire-Disability Index (HAQ-DI) will be evaluated at all visits by using descriptive statistics. The change between visits will be evaluated by Repeated Measures ANOVA test. |
| Work productivity (measured with WPAI-PSO) at Week 16 | 16 week | Work productivity (WPAI-PSO) at week 16 will be evaluated by using descriptive statistics at week 16. Changes at work productivity through the visits will be inspected by using Repeated Measures ANOVA test. |
Other
| Measure | Time frame | Description |
|---|---|---|
| In case of insulin resistance determined at the baseline, the change in the resistance level as measured by HOMA-IR | 16 week | Change in HOMA-IR level between baseline and week 16 will be evaluated |
Outcome results
None listed